Epidemiology and Treatment Options for COVID-19: A Review
), Peace A. Olajide(2), Elukunbi H. Awoyelu(3), Oluwatosin A. Adetuyi(4), Oluwaseun A. Adebisi(5),
(1) Department of Natural Sciences, Faculty of Pure and Applied Sciences, Precious Cornerstone University, Ibadan,
(2) Department of Natural Sciences, Faculty of Pure and Applied Sciences, Precious Cornerstone University, Ibadan,
(3) Department of Natural Sciences, Faculty of Pure and Applied Sciences, Precious Cornerstone University, Ibadan,
(4) Department of Biochemistry, Osun State University, Osogbo, Osun State,
(5) Department of Biochemistry, Osun State University, Osogbo, Osun State,
Corresponding Author
Abstract
The Coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. As of 19 June 2020 data from the World Health Organization (WHO) have shown that more than 8457305 confirmed cases have been identified in more than 200 countries, with the number of cases cutting across all continents. On 30th January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses; therefore, bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human-to-human transfer has been confirmed widely via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond. (Afr J Reprod Health 2020 (Special Edition); 24[2]: 142-153).
References
Lu H, Stratton CW and Tang YW. Outbreak of
pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 2020 Jan 16; [Epub ahead of print]. doi: 10.1002/jmv.25678.
Li Q, Guan X, Wu P, Wang X, Zhou L and Tong
Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29; [Epub ahead of print]. doi: 10.1056/NEJMoa2001316.
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ,
Drosten C and Gulyaeva AA. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. bioRxiv 2020 Feb 11; doi: 10.1101/2020.02.07.937862.
Chen N, Zhou M, Dong X, Qu J, Gong F and Han
Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13. doi: 10.1016/ S0140- 6736(20)30211- 7.
Huang C, Wang Y, Li X, Ren L, Zhao J and Hu Y.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497506. doi: 10.1016/S0140-6736(20)30183-5.
Wang C, Horby PW, Hayden FG and Gao GF. A novel
coronavirus outbreak of global health concern. Lancet 2020; 395:470–3. doi: 10.1016/S0140-6736(20)30185-9.
Holshue ML, DeBolt C, Lindquist S, Lofy KH,
Wiesman J and Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020 Jan 31; [Epub ahead of print]. doi: 10.1056/NEJMoa2001191.
Wang D, Hu B, Hu C, Zhu F, Liu X and Zhang J.
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Feb 7; [Epub ahead of print]. doi: 10.1001/jama.2020. 1585.
Chang D, Lin M, Wei L, Xie L, Zhu G and Dela
Cruz CS. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020 Feb 7; [Epub ahead of print]. doi: 10.1001/ jama.2020.1623.
Carlos WG, Dela Cruz CS, Cao B, Pasnick S and
Jamil S. Novel Wuhan (2019- nCoV) coronavirus. Am J Respir Crit Care Med 2020; 201: P7–8. doi: 10.1164/ rccm.2014P7.
Zhao S, Lin Q, Ran J, Musa SS, Yang G and
Wang W. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020; 92:214–17. doi: 10.1016/j.ijid.2020.01.050.
Biscayart C, Angeleri P, Lloveras S, Chaves T,
Schlagenhauf P and Rodriguez- Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? —Interim recommendations January 2020, from the Latin-American Society for Travel Medicine (SLAMVI). Travel Med Infect Dis 2020;101567. doi: 10.1016/j.tmaid.2020.101567.
Munster VJ, Koopmans M, van Doremalen N, van
Riel D and de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med 2020 Jan 24; [Epub ahead of print]. doi: 10.1056/NEJMp20 0 0929.
Yoo JH. The fight against the 2019-nCoV outbreak: an
arduous march has just begun. J Korean Med Sci 2020; 35:e56. doi: 10.3346/jkms.2020.35. e56.
Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina
B and Caro V. First cases of Middle East respiratory syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human trans-mission, Euro Surveill. 2013; 18:20502.
Buchholz U, Müller MA, Nitsche A, Sanewski A,
Wevering N and Bauer-Balci T. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill. 2013; 18:20406.
Saif LJ. Animal coronaviruses: what can they teach us
about the severe acute respiratory syndrome? Rev Sci Tech. 2004; 23:643–60.
Gwaltney JM Jr. Virology and immunology of the
common cold. Rhinology. 1985; 23:265.
Tyrrell DAJ and Myint SH. Chapter 60: Coronaviruses.
In Barson 1 S, editor. Medical microbiology. 4th edition. Galveston: University of Texas Medical Branch at Galveston; 1996.
Lee KH, Yoo SG, Cho Y, Kwon DE, La Y and
Han SH. Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. J Microbiol Im- munol Infect 2019 Jun 19; [Epub ahead of print]. doi: 10.1016/j.jmii.2019.05.007.
Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC
and Chang WS. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect 2019; 52:172–99. doi: 10.1016/j.jmii.2018.11.004.
Lee JY, Yang PC, Chang C, Lin IT, Ko WC and
Cia CT. Community-acquired adenoviral and pneumococcal pneumonia complicated by pulmonary aspergillo- sis in an immunocompetent adult. J Microbiol Immunol Infect 2019; 52:838–9. doi: 10.1016/j.jmii.2019.05.014.
Su IC, Lee KL, Liu HY, Chuang HC, Chen LY and
Lee YJ. Severe community- acquired pneumonia due to Pseudomonas aeruginosa coinfection in an influenza A(H1N1)pdm09 patient. J Microbiol Immunol Infect 2019; 52:365–6. doi: 10.1016/j.jmii.2018.05.007.
Lee SH, Ruan SY, Pan SC, Lee TF, Chien JY and
Hsueh PR. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units. J Microbiol Immunol Infect 2019; 52:920–8. doi: 10.1016/j.jmii.2019.10.009.
Hung HM, Yang SL, Chen CJ, Chiu CH, Kuo CY
and Huang KA. Molecular epidemiology and clinical features of rhinovirus infections among hospitalized patients in a medical center in Taiwan. J Microbiol Immunol Infect 2019; 52:233–41. doi: 10.1016/j.jmii.2018.08.009.
Lin GL, Lu CY, Chen JM, Lee PI, Ho SY and
Weng KC. Molecular epidemiology and clinical features of adenovirus infection in Taiwanese children, 2014. J Microbiol Immunol Infect 2019; 52:215–24. doi: 10.1016/j.jmii.2018.07.005.
Chan JF, Kok KH, Zhu Z, Chu H, To KK and
Yuan S. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9:22136. doi: 10.1080/22221751.2020.1719902.
Lu R, Zhao X, Li J, Niu P, Yang B and Wu H.
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Jan 30; [Epub ahead of print]. doi: 10.1016/ S0140- 6736(20)30251- 8.
Zhu N, Zhang D, Wang W, Li X, Yang B and
Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020 Jan 24; [Epub ahead of print]. doi: 10.1056/NEJMoa2001017.
Jiang S, Du L and Shi Z. An emerging coronavirus
causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect 2020; 9:275–7. doi: 10.1080/22221751.2020.1723441.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L and
Xu T. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020 Jan 30; [Epub ahead of print]. doi: 10.1097/CM9. 0 0 0 0 0 0 0 0 0 0 0 0 0722.
Chen L, Liu W, Zhang Q, Xu K, Ye G and Wu
W. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 2020; 9:313–19. doi: 10.1080/ 22221751.2020.1725399.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L and
Zhang W. A pneumonia out- break associated with a new coronavirus of probable bat origin. Nature 2020 Feb 3; [Epub ahead of print]. doi: 10.1038/s41586- 020- 2012- 7.
Centers for Disease Control and Prevention (CDC).
Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep. 2003; 52(12):241–6.
World Health Organization. Coronavirus never before
seen in humans is the cause of SARS– update 31. Geneva: The Organization; 2003.
World Health Organization Situation report. Available
at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation reports (2020).
Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY and Lim
W. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361:1319– 25
Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA and
Dijkman R. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440):251–4.
Perlman S and Netland J. Coronaviruses post-SARS:
update on replication and pathogenesis. Nat Rev Microbiol 2009;7(6):439–50.
Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E
and Pfefferle S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85(9):4122–34.
Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss
K and Nehlmeier I. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 2011; 85 (24):13363–72.
Wu F, Zhao S, Yu B, Chen Y-M, Wang W and Song Z-
G. A new coronavirus associated with human respiratory disease in China. Nature 2020; 1–5.
Zhou P, Yang X, Wang X, Hu B, Zhang L and Zhang W.
A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020; Feb: 3.
Xu X, Chen P, Wang J, Feng J, Zhou H and Li X.
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences 2020; 63 (3):457–60.
Wan Y, Shang J, Graham R, Baric RS and Li F.
Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020.
WuA, Peng Y, Huang B, Ding X, Wang X and Niu P.
Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020.
Lu R, Zhao X, Li J, Niu P, Yang B and Wu H. Genomic
characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224):565–74.
Chen Y, Liu Q and Guo D. Emerging coronaviruses:
genome structure, replication, and pathogenesis. J Med Virol 2020.
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R and
Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of
Infectious Diseases. 2020; 91:264–6.
Li B, Si H-R, Zhu Y, Yang X-L, Anderson DE and Shi
Z-L. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next Generation Sequencing. mSphere. 2020; 5(1).
Gralinski LE and Menachery VD. Return of the
coronavirus: 2019-nCoV. Viruses 2020; 12(2):135.
Xu X, Chen P, Wang J, Feng J, Zhou H and Li X.
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 1–4.
Sun P, Qie S and Liu Z. Clinical characteristics of 50466
hospitalized patients with 2019-nCoV infection. J Med Virol. 2020. https ://doi.org/10.1002/jmv.25735.
Wang D and Hu B. Clinical characteristics of 138
hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; https ://doi.org/10.1001/jama.2020.1585.
Mulangu S, Dodd LE and Davey RT Jr. A randomized,
controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381(24):2293–303.
Gordon CJ, Tchesnokov EP and Feng JY. The antiviral
compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020; https ://doi.org/10.1074/jbc.AC120 .01305 6.
Wit E, Feldmann F and Cronin J. Prophylactic and
therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020. https ://doi.org/10.1073/pnas.19220 83117.
Sheahan TP, Sims AC and Leist SR. Comparative
therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Communs. 2020; 11(1):222.
Holshue ML, DeBolt C and Lindquist S. First case of
novel coronavirus in the United States. N Engl J Med. 2020; 382(10):929–36.
Cao B. Mild/moderate 2019-nCoV remdesivir RCT—
Full Text View ClinicalTrials.gov. 2020. https ://clinicaltrials.gov/ct2/show/NCT04 25266 4. Accessed 13 Feb 2020.
Li W, Moore MJ and Vasilieva N. Angiotensin-
converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450–4.
Dimitrov DS. The secret life of ACE2 as a receptor for
the SARS virus. Cell. 2003; 115(6):652–3.
Simmons G, Reeves JD and Rennekamp AJ.
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA. 2004; 101(12):4240–5.
Yeung KS, Yamanaka GA and Meanwell NA. Severe
acute respiratory syndrome coronavirus entry into host cells: opportunities for therapeutic intervention. Med Res Rev. 2006; 26(4):414–33.
Yan Y, Zou Z and Sun Y. Anti-malaria drug chloroquine
is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013; 23(2):300–2.
Vincent MJ, Bergeron E and Benjannet S. Chloroquine
is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2:69.
Xu H, Zhong L and Deng J. High expression of ACE2
receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1):8.
Wang M, Cao R and Zhang L. Remdesivir and
chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. https ://doi.org/10.1038/s4142 2-020-0282-0.
Gao J, Tian Z and Yang X. Breakthrough: chloroquine
phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72–3.
W. S. Chloroquine Prevention of Coronavirus Disease
(COVID-19) in the Healthcare Setting (COPCOV). 2020. https ://clinicaltrials.gov/ct2/show/NCT04 30350 7. Accessed 11 Mar 2020.
Ponticelli C and Moroni G. Hydroxychloroquine in
systemic lupus erythematosus (SLE). Expert Opin Drug Saf.
; 16(3):411–9.
Schrezenmeier E and Dorner T. Mechanisms of action of
hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155–66.
Yao X, Ye F and Zhang M. In vitro antiviral activity and
projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https ://doi.org/10.1093/cid/ciaa2 37.
Hernandez-Cardenas C. Hydroxychloroquine Treatment
for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA). 2020. https ://clinicaltrials.gov/ct2/show/NCT04 31589 6. Accessed 20 Mar 2020.
Liu J, Manheimer E and Shi Y. Chinese herbal medicine
for severe acute respiratory syndrome: a systematic review and meta-analysis. J Altern Complem Med. 2004; 10(6):1041–51.
Ji S, Bai Q and Wu X. Unique synergistic antiviral
effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother. 2020; 121:109652.
Ding Y, Zeng L and Li R. The Chinese prescription
lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17(1):130.
Du CY, Zheng KY and Bi CW. Yu Ping Feng San, an
ancient Chinese herbal decoction induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res. 2015; 29(5):656–61.
Wang C, Cao B and Liu QQ. Oseltamivir compared with
the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011; 155(4):217–25. 79.
Huang C, Wang Y and Li X. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506.
Chen N, Zhou M and Dong X. Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13
Article Metrics
Abstract View
: 1122 times
Download : 382 times
Refbacks
- There are currently no refbacks.
